| Cat. No. |
Product Name |
Information |
| PC-20170 |
MRI-1891
|
MRI-1891 (INV-202) is potent, selective, β-Arrestin-2-biased peripheral cannabinoid-1 receptor (CB1R) antagonist with Ki of 0.3 nM (hCB1R), >2000-fold CB1R/CB2R selectivity. |
| PC-49218 |
S-777469
|
S-777469 (S777469) is a potent, selective, orally available cannabinoid receptor 2 (CB2) receptor agonist with Ki value of 32 nM (hCB2), >100-fold selectivity over CB1. |
| PC-47097 |
LY2828360
|
LY2828360 is a potent CB2 receptor agonist with similar affinity for human and rat CB2 receptors with Ki of 40.3 nM and 36.7 nM, respectively, shows EC50 of 20.1 nM in [35S]-GTPγS assays. |
| PC-73454 |
Vicasinabin
|
Vicasinabin (RG7774, RG-7774) is a potent, selective agonist of cannabinoid receptor 2 (CB2) with cAMP EC50 of 1 nM (hCB2), >800-fold selectivity over CB1 receptor. |
| PC-73251 |
ZCZ011
|
ZCZ011 is a positive allosteric modulator of CB1 receptor, increases specific binding of CB1 receptor orthosteric agonist [3H]CP55,940 to mouse brain membranes with pEC50 of 6.9. |
| PC-72731 |
PSNCBAM-1
|
PSNCBAM-1 is an allosteric antagonist of CB1 receptor with IC50 of 22.5 nM in Ca2+ assays, inhibits [3H]CP55,940 binding with EC50 of 167 nM. |
| PC-72730 |
RTICBM-189
|
RTICBM-189 is a potent, selective, brain-penetrant CB1 negative allosteric modulator (NAM) with pIC50 of 7.54 in Ca2+ assay, 5.29 in GTPγS assay. |
